中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2014年
9期
693-696
,共4页
黄和%孙维建%卢明东%李丕宏%倪仲琳%张伟%郑志强
黃和%孫維建%盧明東%李丕宏%倪仲琳%張偉%鄭誌彊
황화%손유건%로명동%리비굉%예중림%장위%정지강
胃肿瘤%化疗栓塞,治疗性%肿瘤转移%抗肿瘤联合化疗方案
胃腫瘤%化療栓塞,治療性%腫瘤轉移%抗腫瘤聯閤化療方案
위종류%화료전새,치료성%종류전이%항종류연합화료방안
Stomach neoplasms%Chemoembolization,therapeutic%Neoplasm metastasis%Antineoplastic combined chemotherapy protocols
目的 评价静脉化疗联合肝动脉化疗栓塞治疗胃癌伴肝转移的有效性和安全性.方法 将60例胃癌伴肝转移患者分成2组:试验组30例,经肝动脉化疗栓塞治疗后行静脉化疗,化疗方案:多西他赛60 mg/m2静脉滴注,第1天;奥沙利铂80 mg/m2静脉滴注,第1天;5-氟尿嘧啶500 mg/m2静脉滴注,第1~5天;对照组30例,按上述方案行静脉化疗.4周为1个周期,对所有病例化疗2~6个周期后评价疗效和毒副反应.结果 试验组化疔总有效率53%,卡氏评分提高率70%,对照组分别为37%和40%,差异均有统计学意义(均P<0.05);试验组中位总生存时间为13个月,对照组为8个月,差异有统计学意义(P<0.05).试验组的毒副反应无明显增加.结论 静脉化疗联合肝动脉化疗栓塞治疗胃癌伴肝转移较单纯静脉化疗疗效明显增加,毒副反应轻且易于控制.
目的 評價靜脈化療聯閤肝動脈化療栓塞治療胃癌伴肝轉移的有效性和安全性.方法 將60例胃癌伴肝轉移患者分成2組:試驗組30例,經肝動脈化療栓塞治療後行靜脈化療,化療方案:多西他賽60 mg/m2靜脈滴註,第1天;奧沙利鉑80 mg/m2靜脈滴註,第1天;5-氟尿嘧啶500 mg/m2靜脈滴註,第1~5天;對照組30例,按上述方案行靜脈化療.4週為1箇週期,對所有病例化療2~6箇週期後評價療效和毒副反應.結果 試驗組化疔總有效率53%,卡氏評分提高率70%,對照組分彆為37%和40%,差異均有統計學意義(均P<0.05);試驗組中位總生存時間為13箇月,對照組為8箇月,差異有統計學意義(P<0.05).試驗組的毒副反應無明顯增加.結論 靜脈化療聯閤肝動脈化療栓塞治療胃癌伴肝轉移較單純靜脈化療療效明顯增加,毒副反應輕且易于控製.
목적 평개정맥화료연합간동맥화료전새치료위암반간전이적유효성화안전성.방법 장60례위암반간전이환자분성2조:시험조30례,경간동맥화료전새치료후행정맥화료,화료방안:다서타새60 mg/m2정맥적주,제1천;오사리박80 mg/m2정맥적주,제1천;5-불뇨밀정500 mg/m2정맥적주,제1~5천;대조조30례,안상술방안행정맥화료.4주위1개주기,대소유병례화료2~6개주기후평개료효화독부반응.결과 시험조화정총유효솔53%,잡씨평분제고솔70%,대조조분별위37%화40%,차이균유통계학의의(균P<0.05);시험조중위총생존시간위13개월,대조조위8개월,차이유통계학의의(P<0.05).시험조적독부반응무명현증가.결론 정맥화료연합간동맥화료전새치료위암반간전이교단순정맥화료료효명현증가,독부반응경차역우공제.
Objective To evaluate efficacy and safety of intravenous chemotherapy combined with TACE in the treatment of gastric cancer with hepatic metastasis.Methods In this study 60 gastric cancer patients with hepatic metastasis were divided into two groups randomly,the trial group (30 cases) took intravenous chemotherapy consisted of docetaxel 60 mg/m2 intravenous drip d1,oxaliplatin 80 mg/m2 intravenous drip d1 followed by 5-fiuorouracil 500 mg/m2 intravenous drip d1-5 after TACE.The control group (30 cases) took the same chemotherapy protocol and one treatment cycle covering 4 weeks.Results The overall response rate in trial group was 53% and the increase rate of Karnofsky was 70% while that was 37% and 40% respectively in the control group (P < 0.05).The median overall survival of trial group was 13 months and which was 8 months in the control group (P < 0.05),meanwhile the toxicities and side reactions of trial group didn't increase notably.Conclusions Intravenous chemotherapy combined with TACE is safe and more effective in the treatment of gastric cancer with hepatic metastasis.